Want to see HK:1696 full AI Analyst Report?
Top Page
Sisram Medical Ltd.
(1696)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$2.50
▼(-35.40% Downside)
Action:Reiterated
Date:05/21/26
The score is driven primarily by mixed fundamentals: a strong, low-leverage balance sheet is offset by significant margin compression and notably weaker 2025 operating/free cash flow. Technicals are a major drag due to a clear downtrend and bearish momentum, while valuation provides partial support with a moderate P/E and a ~4.5% dividend yield.
Positive Factors
Low leverage / strong balance sheet
Very low debt-to-equity (~0.11) and an expanding equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports capital spending or acquisitions, and allows the firm to sustain investments in product development and distributor support during demand cycles.
Negative Factors
Margin compression / lower net profitability
A material decline from double-digit to ~5.2% net margin signals structural pressure from higher operating costs, pricing stress, or mix shifts. Persistently compressed margins reduce retained earnings, constrain reinvestment capacity, and weaken returns to shareholders absent sustained margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt-to-equity (~0.11) and an expanding equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports capital spending or acquisitions, and allows the firm to sustain investments in product development and distributor support during demand cycles.
Read all positive factors
Sisram Medical Ltd. (1696) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.11B
Dividend Yield2.82%
Average Volume (3M)469.37K
Price to Earnings (P/E)7.1
Beta (1Y)1.14
Revenue Growth4.57%
EPS Growth-24.35%
CountryHK
Employees1,000
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.04
Shares Outstanding468,343,080
10 Day Avg. Volume515,040
30 Day Avg. Volume469,367
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)0.53
Price to Sales (P/S)0.69
P/FCF Ratio37.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.52
Revenue Forecast (FY)HK$3.20B
Sisram Medical Ltd. Business Overview & Revenue Model
Company Description
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops...
How the Company Makes Money
Sisram Medical makes money primarily by selling medical aesthetic systems (capital equipment) and by generating recurring revenue tied to the installed base of those systems. Key revenue streams typically include: (1) Sales of energy-based aesthet...
Sisram Medical Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
82
Very Positive
Cash Flow
49
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 365.35M | 349.11M | 359.29M | 354.48M | 294.29M |
| Gross Profit | 215.14M | 216.68M | 219.53M | 202.23M | 166.86M |
| EBITDA | 38.22M | 38.91M | 53.43M | 58.38M | 55.96M |
| Net Income | 19.02M | 25.13M | 31.50M | 40.17M | 31.25M |
Balance Sheet | |||||
| Total Assets | 657.17M | 627.26M | 613.50M | 555.60M | 530.13M |
| Cash, Cash Equivalents and Short-Term Investments | 70.96M | 71.98M | 70.60M | 91.49M | 157.96M |
| Total Debt | 51.75M | 43.20M | 44.68M | 41.34M | 41.62M |
| Total Liabilities | 153.55M | 142.47M | 143.98M | 123.38M | 126.51M |
| Stockholders Equity | 479.79M | 464.03M | 452.31M | 430.87M | 402.18M |
Cash Flow | |||||
| Free Cash Flow | 6.82M | 30.38M | 35.37M | -42.28M | 29.41M |
| Operating Cash Flow | 9.40M | 33.08M | 43.94M | 22.04M | 32.38M |
| Investing Cash Flow | -1.70M | -6.59M | -32.99M | -52.11M | -46.77M |
| Financing Cash Flow | -10.92M | -16.11M | -20.97M | -17.85M | 55.78M |
Sisram Medical Ltd. Technical Analysis
Negative
3.87
Price Trends
2.70
Negative
3.19
Negative
3.95
Negative
Market Momentum
-0.13
Negative
42.62
Neutral
45.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1696, the sentiment is Negative. The current price of 3.87 is above the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.70, and below the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 45.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1696.
Sisram Medical Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$746.83M | 6.56 | 5.74% | 3.48% | -3.30% | 6.27% | |
61 Neutral | HK$1.11B | 7.08 | 4.02% | 2.82% | 4.57% | -24.35% | |
57 Neutral | HK$348.56M | 9.09 | 4.14% | ― | 2.17% | 109.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$128.13M | -1.62 | -17.70% | ― | -38.20% | -108.24% | |
47 Neutral | HK$762.95M | -1.26 | -21.29% | ― | -34.96% | 42.74% | |
44 Neutral | HK$2.91B | -11.83 | -11.27% | ― | 16.35% | 9.84% |
* Healthcare Sector Average
HK:1696
Sisram Medical Ltd.
2.38
-1.74
-42.23%
HK:9996
Peijia Medical Ltd.
4.32
-2.52
-36.84%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.06
-0.07
-54.17%
HK:2407
Gaush Meditech Ltd.
5.05
-1.43
-22.07%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.73
-0.82
-32.16%
HK:6118
Austar Lifesciences Ltd.
0.68
-0.02
-2.86%
Sisram Medical Ltd. Corporate Events
Sisram Medical shareholders approve all AGM resolutions, renew buyback and issuance mandates
Jun 24, 2026
Sisram Medical Ltd. reported that all resolutions put to shareholders at its annual general meeting on 24 June 2026 were approved by poll, including the receipt of its 2025 audited financial statements and the re-election of key executive and non-...
Sisram Medical Calls EGM to Approve New Supply Framework Agreement
Jun 23, 2026
Sisram Medical Ltd. has called an extraordinary general meeting in Hong Kong on 3 August 2026 for shareholders to vote on approving and ratifying a new supply framework agreement between its subsidiary Sisram Medical HK Limited and Fosun Wanbang (...
Sisram Medical delays dispatch of circular on new supply framework agreement
Jun 12, 2026
Sisram Medical Ltd. has announced a delay in sending to shareholders a circular detailing its new supply framework agreement and related proposed annual caps. The document, which will also contain opinions from an independent board committee and a...
Sisram Medical Seeks Independent Shareholder Nod for New Botulinum Toxin Supply Deal
May 22, 2026
Sisram Medical’s Hong Kong subsidiary has entered into a new supply framework agreement with Fosun Wanbang (Jiangsu), an indirect wholly owned unit of controlling shareholder Fosun Pharma, to continue supplying botulinum toxin type A for inj...
Sisram Medical Sets June 2026 AGM to Seek Share Repurchase and Issuance Mandates
May 19, 2026
Sisram Medical Ltd. has convened its annual general meeting for 24 June 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and consider the re-election of four directors, includin...
Sisram Medical Completes Internal Shareholding Reorganisation Under Fosun Pharma
Apr 22, 2026
Sisram Medical has announced the completion of a reorganisation at the controlling shareholder level involving internal transfers of its shares among Fosun Pharma’s indirect wholly owned subsidiaries. Ample Up and Chindex have transferred th...
Fosun Pharma Streamlines 71.42% Stake in Sisram Medical Through Internal Reorganisation
Apr 8, 2026
Sisram Medical Ltd. announced a planned internal reorganisation at its controlling shareholder Fosun Pharma, under which two indirect wholly owned subsidiaries, Ample Up Limited and Chindex Medical Limited, will transfer their entire combined 71.4...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.